A Study of Thyroid Profile with Chronic Kidney Disease in a tertiary care hospital in northern India

Background Chronic Kidney Disease (CKD) includes a spectrum of different patho-physiological events associated with abnormal renal functions and a progressive decrease in effective glomerular filtration rate. It is a condition defined by abnormalities of kidney structure or function for more than 3 months

Deep learning based hybrid analysis of malware detection and classification: A recent review

Globally extensive digital revolutions involved with every process related to human progress can easily create the critical issues in security aspects. This is promoted due to the important factors like financial crises and geographical connectivity in worse condition of the nations. By this fact, the authors are well motivated to present a precise literature on malware detection with deep learning approach. In this literature, the basic overview includes the nature of nature of malware detection i.e., static, dynamic, and hybrid approach. Another major component of this articles is the investigation of the backgrounds from recently published and highly cited state-of-the-arts on malware detection, prevention and prediction with deep learning frameworks. The technologies engaged in providing solutions are utilized from AI based frameworks like machine learning, deep learning, and hybrid frameworks. The main motivations to produce this article is to portrait clear pictures of the option challenging issues and corresponding solution for developing robust malware-free devices. In the lack of a robust malware-free devices, highly growing geographical and financial disputes at wide globes can be extensively provoked by malicious groups. Therefore, exceptionally high demand of the malware detection devices requires a very strong recommendation to ensure the security of a nation. In terms preventing and recovery, Zero-day threats can be handled by recent methodology used in deep learning. In the conclusion, we also explored and investigated the future patterns of malware and how deals with in upcoming years. Such review may extend towards the development of IoT based applications used many fields such as medical devices, home appliances, academic systems

CFD Study of Liquid Sodium inside a Wavy Tube for Laminar Convectors: Effect of Reynolds Number, Wave Pitch, and Wave Amplitude

Metallic tubes have been widely used as primary heat transfer elements in laminar convectors for domestic and aerospace heating purpose. This paper uses CFD tool to investigate the heat output and pressure drop of liquid sodium flowing inside a circular tube having a wavy profile throughout its length. The wavy tube can be utilized in laminar liquid metal convectors as basic heat transfer element. The effect of Reynolds number (500≤Re≤2000) wave pitch (25 mm≤λ≤100 mm) and wave amplitude (2 mm≤a≤6 mm) on the heat output and pressure drop has been numerically studied. Based on the CFD results important controlling parameters have been identified and it is concluded that the heat output from the wavy tube is affected by the wave pitch and the wave amplitude while the pressure drop is mostly affected by the Reynolds number and wave amplitude

Towards the Digital Twin (DT) of narrow-band Internet of Things (NBIoT) wireless communication in industrial indoor environment

A study of the behavior of NB-IoT wireless communication in an industrial indoor environment was conducted in this paper. With Wireless Insite software, a scenario in the industrial sector was simulated and modeled. Our research examined how this scenario or environment affected the communication parameters of NB-IoT’s physical layer. In this context, throughput levels among terminals as well as between terminals and transceiver towers, the power received at signal destination points, signal-to-noise ratios (SNRs) in the environment, and distances between terminals and transceivers are considered. These simulated results are also compared with the calculated or theoretical values of these parameters. The results show the effect of the industrial setting on wireless communication. The differences between the theoretical and simulated values are also established

Mobility management-based autonomous energy-aware framework using machine learning approach in dense mobile networks

A paramount challenge of prohibiting increased CO2 emissions for network densification is to deliver the Fifth Generation (5G) cellular capacity and connectivity demands, while maintaining a greener, healthier and prosperous environment. Energy consumption is a demanding consideration in the 5G era to combat several challenges such as reactive mode of operation, high latency wake up times, incorrect user association with the cells, multiple cross-functional operation of Self-Organising Networks (SON), etc. To address this challenge, we propose a novel Mobility Management-Based Autonomous Energy-Aware Framework for analysing bus passengers ridership through statistical Machine Learning (ML) and proactive energy savings coupled with CO2 emissions in Heterogeneous Network (HetNet) architecture using Reinforcement Learning (RL). Furthermore, we compare and report various ML algorithms using bus passengers ridership obtained from London Overground (LO) dataset. Extensive spatiotemporal simulations show that our proposed framework can achieve up to 98.82% prediction accuracy and CO2 reduction gains of up to 31.83%

Edge intelligence in private mobile networks for next generation railway systems

The integration of Private Mobile Networks (PMN) with edge intelligence is expected to play an instrumental role in realizing the next generation of industry applications. This combination collectively termed as Intelligent Private Networks (IPN) deployed within the scope of specific industries such as transport systems can unlock several use-cases and critical applications that in turn can address rising business demands. This article presents a conceptual IPN that hosts intelligence at the network edge employing emerging technologies that satisfy a number of Next Generation Railway System (NGRS) applications. NGRS use-cases along with their applications and respective beyond 5G (B5G) enabling technologies have been discussed along with possible future research and development directions that will allow these promising technologies to be used and implemented widely

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation